Shuangcheng Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHUANGCHENG
SHUANGCHENG has five approved drugs.
Drugs and US Patents for Shuangcheng
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shuangcheng | OCTREOTIDE ACETATE | octreotide acetate | INJECTABLE;INJECTION | 217860-001 | May 2, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Shuangcheng | EPTIFIBATIDE | eptifibatide | INJECTABLE;INJECTION | 213081-002 | Apr 20, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shuangcheng | BORTEZOMIB | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 216528-001 | Dec 17, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shuangcheng | BIVALIRUDIN | bivalirudin | INJECTABLE;INTRAVENOUS | 210031-001 | Oct 23, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shuangcheng | EPTIFIBATIDE | eptifibatide | INJECTABLE;INJECTION | 213081-001 | Sep 7, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shuangcheng | PACLITAXEL | paclitaxel | POWDER;INTRAVENOUS | 216355-001 | May 15, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

